Clinical Trial

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2016-01-19; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2021-06-29
Status change: Not Yet Recruiting → Recruiting 2016-05-11
Trial Details
NCT Number NCT02659293
Lead Sponsor University of Chicago
Conditions Multiple Myeloma
Enrollment 180 participants
Start Date 2016-04-26
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-04